Lung cancer is one of the most commonly diagnosed cancers in the US and accounts for the highest number of cancer related deaths worldwide. NeoGenomics consistently proves to be at the forefront of the lung cancer testing industry with their variety of comprehensive and targeted testing options. No two patients’ cases are the same, and NeoGenomics wholeheartedly believes no patient should be limited to a “one-size-fits-all” approach.
In this OncLive Reach program, non-small cell lung cancer expert Hatim Husain, MD, medical oncologist and associate clinical professor of medicine at Moores Cancer Center, University of California, San Diego, explains the recent dramatic increase in biomarker testing needs, why biomarker testing is so important, and how comprehensive genomic profiling is considered the new standard of care for lung testing. With him, Shari Brown, MD, Director of Molecular Pathology Services at NeoGenomics, details how their offerings such as liquid biopsies maximize tissue preservation and optimize tumor profiling, how they lessen the burden on patients with less invasive testing and innovations such as their national mobile phlebotomy program that kept patients safe during the COVID-19 pandemic, and the barriers patients face in regard to receiving proper testing and care.